Soleno Therapeutics (SLNO) Gross Profit (2016 - 2017)
Historic Gross Profit for Soleno Therapeutics (SLNO) over the last 3 years, with Q2 2017 value amounting to -$41000.0.
- Soleno Therapeutics' Gross Profit rose 1632.65% to -$41000.0 in Q2 2017 from the same period last year, while for Jun 2017 it was $6482.0, marking a year-over-year decrease of 9425.3%. This contributed to the annual value of -$58518.0 for FY2016, which is 12296.72% down from last year.
- Soleno Therapeutics' Gross Profit amounted to -$41000.0 in Q2 2017, which was up 1632.65% from $56000.0 recorded in Q1 2017.
- In the past 5 years, Soleno Therapeutics' Gross Profit ranged from a high of $191000.0 in Q3 2015 and a low of -$70000.0 during Q3 2016
- Moreover, its 3-year median value for Gross Profit was -$5000.0 (2015), whereas its average is $19827.1.
- Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Gross Profit was 50419.43% (2016), while the steepest drop was 45000.0% (2016).
- Quarter analysis of 3 years shows Soleno Therapeutics' Gross Profit stood at -$15211.0 in 2015, then soared by 504.19% to $61482.0 in 2016, then crashed by 166.69% to -$41000.0 in 2017.
- Its Gross Profit was -$41000.0 in Q2 2017, compared to $56000.0 in Q1 2017 and $61482.0 in Q4 2016.